EA202190614A1 - Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря - Google Patents

Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря

Info

Publication number
EA202190614A1
EA202190614A1 EA202190614A EA202190614A EA202190614A1 EA 202190614 A1 EA202190614 A1 EA 202190614A1 EA 202190614 A EA202190614 A EA 202190614A EA 202190614 A EA202190614 A EA 202190614A EA 202190614 A1 EA202190614 A1 EA 202190614A1
Authority
EA
Eurasian Patent Office
Prior art keywords
paclitaxel
treatment
hyaluronic acid
bladder cancer
prodrug
Prior art date
Application number
EA202190614A
Other languages
English (en)
Inventor
Джорджо Москони
Даниела Ябес
Карло Пиццокаро
Original Assignee
Фидия Фармачеутичи С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фидия Фармачеутичи С.П.А. filed Critical Фидия Фармачеутичи С.П.А.
Publication of EA202190614A1 publication Critical patent/EA202190614A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Описана фармацевтическая композиция, по сути состоящая из пролекарства на основе паклитаксела, в сочетании с фармакологически приемлемыми разбавителями/вспомогательными веществами для применения в лечении мышечно-неинвазивного рака мочевого пузыря (NMIBC) посредством внутрипузырных инстилляций в соответствии с одной дозой в неделю, составляющей 600 мг, указанного пролекарства или двумя дозами в неделю, в сумме составляющими 1200 мг, в течение 12 или 6 последовательных недель лечения. Применяемое пролекарство на основе паклитаксела получено в соответствии со способом непрямого синтеза с использованием молекул гиалуроновой кислоты (HA) и паклитаксела посредством введения спейсера (4-броммасляной кислоты) между гиалуроновой кислотой и химиотерапевтическим средством.
EA202190614A 2018-10-25 2019-10-23 Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря EA202190614A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102018000009731A IT201800009731A1 (it) 2018-10-25 2018-10-25 Coniugato paclitaxel - acido ialuronico nel trattamento del carcinoma vescicale non infiltrante
PCT/IB2019/059073 WO2020084525A1 (en) 2018-10-25 2019-10-23 Paclitaxel-hyaluronic acid conjugate in the treatment of non-muscle invasive bladder cancer

Publications (1)

Publication Number Publication Date
EA202190614A1 true EA202190614A1 (ru) 2021-06-03

Family

ID=65324453

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190614A EA202190614A1 (ru) 2018-10-25 2019-10-23 Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря

Country Status (20)

Country Link
US (4) US20200397909A1 (ru)
EP (1) EP3870233B1 (ru)
JP (1) JP7518815B2 (ru)
KR (1) KR20210083249A (ru)
CN (1) CN112805035A (ru)
CA (1) CA3112188A1 (ru)
DK (1) DK3870233T3 (ru)
EA (1) EA202190614A1 (ru)
ES (1) ES2971217T3 (ru)
FI (1) FI3870233T3 (ru)
HR (1) HRP20240188T1 (ru)
HU (1) HUE066288T2 (ru)
IT (1) IT201800009731A1 (ru)
LT (1) LT3870233T (ru)
MA (1) MA63879B1 (ru)
PL (1) PL3870233T3 (ru)
PT (1) PT3870233T (ru)
RS (1) RS65193B1 (ru)
SI (1) SI3870233T1 (ru)
WO (1) WO2020084525A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000007747A1 (it) * 2020-04-10 2021-10-10 Fidia Farm Spa Coniugato acido ialuronico-paclitaxel nel trattamento del mesotelioma
IT202000008209A1 (it) * 2020-04-17 2021-10-17 Fidia Farm Spa Procedimento di sintesi di un coniugato acido ialuronico-paclitaxel

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3482812D1 (de) 1983-10-11 1990-08-30 Fidia Spa Fraktionen von hyaluronsaeure mit pharmazeutischer aktivitaet, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
IT1263393B (it) 1993-07-30 1996-08-05 Fidia Advanced Biopolymers Srl Processo per la preparazione e purificazione di acido ialuronico ad alto peso molecolare
ITPD20020271A1 (it) * 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
AR047938A1 (es) * 2003-08-25 2006-03-15 Combinatorx Inc Formulaciones, conjugados y combinaciones de farmacos para el tratamiento de neoplasmas
IT1402384B1 (it) 2010-09-09 2013-09-04 Fidia Farmaceutici Processo per la produzione di acido ialuronico in escherichia coli o bacillus megaterium
IT1402385B1 (it) 2010-09-09 2013-09-04 Fidia Farmaceutici Processo per la produzione di acido ialuronico in escherichia coli o bacillus subtilis
IT201600079633A1 (it) 2016-07-28 2018-01-28 Fidia Farm Spa Procedimento di preparazione e purificazione del sale sodico dell’acido ialuronico

Also Published As

Publication number Publication date
JP2022503771A (ja) 2022-01-12
IT201800009731A1 (it) 2020-04-25
EP3870233A1 (en) 2021-09-01
US20210196833A1 (en) 2021-07-01
WO2020084525A1 (en) 2020-04-30
US20210268119A1 (en) 2021-09-02
EP3870233B1 (en) 2023-12-06
HRP20240188T1 (hr) 2024-05-10
CA3112188A1 (en) 2020-04-30
DK3870233T3 (da) 2024-02-05
ES2971217T3 (es) 2024-06-04
HUE066288T2 (hu) 2024-07-28
LT3870233T (lt) 2024-02-26
PT3870233T (pt) 2024-02-01
CN112805035A (zh) 2021-05-14
KR20210083249A (ko) 2021-07-06
JP7518815B2 (ja) 2024-07-18
US20200397909A1 (en) 2020-12-24
MA63879B1 (fr) 2024-02-29
FI3870233T3 (fi) 2024-02-07
PL3870233T3 (pl) 2024-05-06
SI3870233T1 (sl) 2024-03-29
US20240123077A1 (en) 2024-04-18
RS65193B1 (sr) 2024-03-29

Similar Documents

Publication Publication Date Title
WO2020126620A3 (en) Improved antibody-oligonucleotide conjugate
BR112022014398A2 (pt) Conjugado de fármaco de derivado de eribulina, método de preparação para o mesmo e aplicação do mesmo em medicina
MX2021009199A (es) Conjugado de farmaco de dos ligandos y uso del mismo.
AR059982A1 (es) Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano
BR112021022335A2 (pt) Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer
AR072442A1 (es) Metodo para la terapia del cancer, uso, kit
NZ595767A (en) Composition for the treatment of prostate cancer
GT200600096A (es) Composicion farmaceutica para el tratamiento del cancer
EA202190614A1 (ru) Конъюгат паклитаксела и гиалуроновой кислоты в лечении мышечно-неинвазивного рака мочевого пузыря
BR112023006337A2 (pt) Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer
ATE485037T1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
EA201300420A1 (ru) Комбинации, которые содержат замещенный n-(2-ариламино) арилсульфонамид
EA201071043A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1
EA202191131A1 (ru) Конъюгаты антитело-лекарственное средство, содержащие производные эктеинасцидина
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
MX2021014161A (es) Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton.
BR112022014772A2 (pt) Dispersão sólida amorfa, composição farmacêutica e processos para a preparação destas
CL2021003032A1 (es) Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
CL2022000781A1 (es) Tratamientos cognitivos medicinales
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
MX2022002555A (es) Conjugados de farmaco de anticuerpo de union a receptor de tipo ii de la hormona anti-mulleriana humana (amhrii) y uso de los mismos en el tratamiento de canceres.
BR112022019864A2 (pt) Composto de oxofenilarsina deuterada e uso do mesmo